O-1601

O-1601
[[File:|frameless|220px|alt=|]]
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

O-1601 is a synthetic compound that has been studied for its potential effects on the endocannabinoid system. It is classified as a cannabinoid receptor agonist, meaning it binds to and activates cannabinoid receptors in the body. These receptors are part of the endocannabinoid system, which plays a role in regulating various physiological processes such as pain, mood, appetite, and memory.

Chemical Structure and Properties

O-1601 is a derivative of the cannabinoid class of compounds. Its chemical structure is characterized by the presence of a core cannabinoid framework with specific functional groups that confer its unique properties. The exact molecular formula and weight are determined by its specific chemical modifications.

Pharmacology

O-1601 acts primarily on the CB1 and CB2 receptors, which are the main cannabinoid receptors in the human body. The CB1 receptors are predominantly found in the central nervous system, while CB2 receptors are more common in peripheral tissues, especially those involved in immune function.

Mechanism of Action

As an agonist, O-1601 binds to these receptors and mimics the action of endogenous cannabinoids, such as anandamide and 2-arachidonoylglycerol. This binding leads to a series of intracellular events that result in the modulation of neurotransmitter release, ultimately affecting various physiological responses.

Therapeutic Potential

Research into O-1601 has suggested potential therapeutic applications in areas such as pain management, neuroprotection, and the treatment of inflammatory conditions. However, further studies are needed to fully understand its efficacy and safety profile.

Research and Development

O-1601 is primarily used in preclinical research settings. Studies have focused on its pharmacokinetics, pharmacodynamics, and potential therapeutic effects. The compound is not currently approved for clinical use in humans.

Safety and Toxicology

The safety profile of O-1601 is not well-established, as it is still under investigation. Preclinical studies are necessary to evaluate its potential toxicological effects and to determine safe dosage ranges.

Legal Status

The legal status of O-1601 varies by country and is subject to change as new research emerges and regulatory frameworks evolve. It is important for researchers to be aware of the legal implications of working with such compounds.

Also see

• Cannabinoid receptor
• Endocannabinoid system
• CB1 receptor
• CB2 receptor
• Anandamide
• 2-arachidonoylglycerol